Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2024

Liu Stephen V, Frohn Claas, Minasi Lori, Fernamberg Kristie, Klink Andrew J, Gajra Ajeet, Savill Kristin M Zimmerman, Jonna Sushma

Abstract excerpt

OBJECTIVES: Neuregulin-1 (NRG1) fusions may drive oncogenesis via constitutive activation of ErbB signaling. Hence, NRG1 fusion-driven tumors may be susceptible to ErbB-targeted therapy. Afatinib (irreversible pan-ErbB inhibitor) has demonstrated activity in individual patients with NRG1 fusion-positive solid tumors. This study collected real-world data on demographics, clinical characteristics, and clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Fusion

Share to Lung Neoplasms

Share to Mutation

Share to Neuregulin-1

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 38219288
DOI: 10.1016/j.lungcan.2024.107469

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.PMID 38219288Read ↗

Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.Semantic proximity Read ↗

Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case reportSemantic proximity Read ↗

Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.Semantic proximity Read ↗

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid TumorsSemantic proximity Read ↗

Detection of NRG1 Gene Fusions in Solid TumorsSemantic proximity Read ↗

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.Semantic proximity Read ↗

Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.Semantic proximity Read ↗

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.Semantic proximity Read ↗

A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.Semantic proximity Read ↗

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.Semantic proximity Read ↗

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.